Skip to main content
    D

    Dare Bioscience Inc (DARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.74
    +0.01 (+1.51%)

    Market Cap: $14.37M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(24/37)
    Avg Surprise
    +7.35%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.27 - $0.10
    3 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.16+12.5%
    60d ago$-0.16+12.5%
    30d ago$-0.16+12.5%
    7d ago$-0.16+12.5%
    Current$-0.14
    Revenue Consensus
    $2M
    Range$0 - $6M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.03
    Range$-0.23 - $0.31
    3 analysts
    Revenue Consensus
    $672340
    Range$-1705330 - $5M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.14---
    Jun 26
    Reported Aug 13
    		$-0.20$-0.33+39.39%Beat+55.6%
    Mar 26
    Reported May 14
    		$-0.20$-0.30+33.33%Beat+60.0%
    Dec 25
    Reported Mar 26
    		$-0.10N/A+76.05%Beat+84.5%
    Sep 25
    Reported Nov 13
    		$-0.28$-0.40+30.00%Beat+49.1%
    Jun 25
    Reported Aug 14
    		$-0.45$-0.58+22.41%Beat+49.4%
    Mar 25
    Reported May 13
    		$-0.50$-0.58+13.79%Beat+40.5%
    Dec 24
    Reported Mar 31
    		$-0.65$-0.63-2.64%Miss-983.3%
    Sep 24
    Reported Nov 14
    		$-0.55$-0.71+22.54%Beat+49.1%
    Jun 24
    Reported Aug 12
    		$-0.89$-0.66-34.85%Miss+25.8%
    Mar 24
    Reported May 14
    		$-0.84$-0.72-16.67%Miss+22.2%
    Dec 23
    Reported Mar 28
    		$-0.06$-0.10+40.00%Beat+68.4%
    Sep 23
    Reported Nov 9
    		$-1.08$-1.20+10.00%Beat-12.5%
    Jun 23
    Reported Aug 10
    		$-1.20$-1.08-11.11%Miss-2100.0%
    Mar 23
    Reported May 11
    		$-1.08$-1.20+10.00%Beat-980.0%
    Dec 22
    Reported Mar 30
    		$-0.19$-0.14-35.71%Miss+91.2%
    Sep 22
    Reported Nov 10
    		$-0.96$-1.36+29.41%Beat+55.6%
    Jun 22
    Reported Aug 9
    		$0.06N/A+107.89%Beat+102.8%
    Mar 22
    Reported May 12
    		$-0.10$-0.14+28.57%Beat+95.2%
    Dec 21
    Reported Mar 31
    		$-2.16$-2.16+0.00%Beat-671.4%
    Sep 21
    Reported Nov 10
    		$-2.16$-2.10-2.86%Miss+25.0%
    Jun 21
    Reported Aug 12
    		$-2.16$-1.96-10.20%Miss+33.3%
    Mar 21
    Reported May 13
    		$-2.07$-2.96+30.07%Beat+4.2%
    Dec 20
    Reported Mar 30
    		$-0.28$-0.13-115.38%Miss-33.3%
    Sep 20
    Reported Nov 12
    		$-2.88$-2.22-29.73%Miss-20.0%
    Jun 20
    Reported Aug 12
    		$-3.24$-2.04-58.82%Miss+6.9%
    Mar 20
    Reported May 14
    		$-2.16$-3.92+44.90%Beat+33.3%
    Dec 19
    Reported Mar 30
    		$-0.21$-0.18-16.67%Miss+16.0%
    Sep 19
    Reported Nov 14
    		$-2.40$-2.48+3.23%Beat+13.0%
    Jun 19
    Reported Aug 14
    		$-3.48$-2.34-48.72%Miss+9.4%
    Mar 19
    Reported Apr 1
    		$-3.24$-3.96+18.18%Beat-268.2%
    Dec 18
    Reported Mar 31
    		$-0.25$-0.27+7.41%Beat+83.1%
    Sep 18
    Reported Nov 13
    		$-2.76$-2.96+6.76%Beat-736.4%
    Jun 18
    Reported Aug 13
    		$-3.84$-2.82-36.17%Miss-1820.0%
    Mar 18
    Reported May 14
    		$-0.88$-0.88+0.00%Beat+67.4%
    Dec 17
    Reported Mar 28
    		$-1.48N/A+52.26%Beat+7.5%
    Sep 17
    Reported Nov 13
    		$-0.33$0.00N/ABeat-
    Jun 17
    Reported Aug 14
    		$-0.20$0.00N/ABeat-
    Mar 17
    Reported May 12
    		$-2.70$-3.10+12.90%Beat-
    Dec 16
    Reported Mar 31
    		$-1.60N/A+52.24%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.95EV/EBITDAN/A
    Price/FCF-0.94xFCF Yield-106.69%
    Profitability
    Profit Margin0.00%Operating Margin-1583.00%
    ROE-2543.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio0.99xQuick Ratio0.99x
    Trading Statistics
    Beta1.01Avg Volume207.33K
    52-Week High$3.7852-Week Low$0.69

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.78
    SMA 20$0.79
    SMA 50$0.85
    SMA 200$1.65
    EMA 10$0.77
    EMA 20$0.78
    EMA 50$0.93
    EMA 200$1.54

    MACD

    Line: -0.03Signal: -0.03Hist: 0.00

    ADX

    ADX: 27.5+DI: 11.4-DI: 23.1

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down8.0
    PSAR$0.86

    Bollinger Bands

    Upper Band$0.88
    Lower Band$0.71
    %B Position2148%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    39.3

    Momentum Oscillators

    Stoch %K21.1
    Stoch %D25.1
    Williams %R-78.3
    ROC (10d)-13.0%
    Momentum-0.11
    CCI (20d)-114.2
    MFI (14d)49.9

    Volatility Measures

    ATR (14d)$0.06(8.1%)
    StdDev (20d)0.04
    Hist Vol66.7%(High)

    Volume Flow

    VWAP$0.74
    OBV69.1M
    AD Line-87.8M
    CMF (20d)-0.146

    Volume Metrics

    Avg Vol (20d)213.6K
    Vol Ratio0.3x(Low)
    VWMA (20d)$0.79

    Pivot Points

    R3$0.76
    R2$0.75
    R1$0.74
    Pivot Point$0.73
    S1$0.72
    S2$0.71
    S3$0.70

    Advanced Oscillators

    TSI-15.13
    Ultimate Osc36.5
    KST18.79

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$187,546$152,455$1.02M$2,262$-21,172$0$-63,647$41,691$22,438$9,302$1.81M$1.00M
    Cost of Revenue$319,889$242,325$295,799$0$0$0$14.22M$0$0$0$21.56M$0
    Gross Profit$-132,343$-89,870$727,877$2,262$-21,172$0$-63,647$41,691$22,438$9,302$1.81M$1.00M
    Operating Expenses$2.84M$2.91M$2.20M$3.67M$3.81M$4.61M$5.32M$4.72M$7.38M$6.03M$6.98M$9.40M
    R&D$241,966$660,462$622,041$1.18M$1.43M$2.30M$3.34M$2.68M$4.93M$3.35M$3.80M$6.67M
    SG&A$2.59M$2.25M$1.58M$2.50M$2.38M$2.31M$2.00M$2.04M$2.45M$2.67M$3.15M$2.70M
    Operating Income$-2,967,980$-2,998,898$-1,471,268$-3,672,148$-3,827,800$-4,581,118$-5,388,197$-4,681,349$-7,359,466$-6,022,473$-5,171,460$-8,396,415
    Interest Income$0$0$0$0$0$0$0$0$20.38M$0$0$0
    Interest Expense$14,793$991$276,570$0$188,683$0$0$21,152$0$732,883$0$0
    Income Before Tax$-2,982,773$-2,999,889$-1,747,838$-3,562,766$-4,016,483$-4,378,307$-3,543,418$-4,702,501$12.91M$-6,755,356$-5,057,562$-8,299,096
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,982,773$-2,999,889$-1,441,718$-3,562,766$-4,016,483$-4,378,307$-5,506,398$-4,702,501$12.91M$-6,755,356$-5,057,562$-8,299,096
    EBITDA$-2,410,630$-2,445,246$-1,213,443$-2,956,609$-3,562,318$-4,202,665$-3,537,050$-4,692,759$-7,432,067$-6,743,919$-5,047,582$-8,289,836
    EBIT$-2,982,773$-2,999,889$-1,747,838$-3,562,766$-4,016,483$-4,378,307$-3,543,418$-4,702,501$-7,468,720$-6,755,356$-5,057,562$-8,299,096
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DARE

    News

    Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

    Daré Bioscience has launched a new "CEO Corner" video series featuring Founder, President, and CEO Sabrina Martucci Johnson. This series aims to provide investors with insights into the company's growing commercial...

    GlobeNewswire•10/13/26•Bullish

    Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

    Daré Bioscience has launched a new "CEO Corner" video series featuring CEO Sabrina Martucci Johnson. The series aims to provide investors with insights into the company's growing commercial portfolio, clinical pipeline...

    GlobeNewswire•10/13/26•Bullish

    Daré Bioscience, Inc. (DARE) stock price, news, quote and history

    Daré Bioscience, Inc. (DARE) stock experienced a drop of 9.58%, trading at $0.7012. The company, focused on women's health therapies...

    Yahoo Finance Singapore•10/9/26•Neutral

    Daré Bioscience Announces Phase 1 Sildenafil Cream Data to Be Presented at SMSNA Annual Fall Scientific Meeting

    Daré Bioscience announced that clinical data from its Phase 1 study of topical Sildenafil Cream will be presented at the Sexual Medicine Society of North America's Annual Fall Scientific Meeting on October 9...

    Quiver Quantitative•10/8/26•Somewhat-Bullish

    Daré Bioscience to present sildenafil cream study data at SMSNA

    Daré Bioscience (NASDAQ: DARE) announced it will present clinical data from a Phase 1 study of its Sildenafil Cream...

    Investing.com•10/8/26•Bullish

    DARE Valuation and Fair Value

    P/E
    -0.9x
    Forward P/E
    1.3x
    P/FCF
    -0.9x
    PEG
    0.0x
    P/B
    -19.6x
    See GNG's fair value

    DARE Profitability: Margins, ROIC and FCF

    Gross margin
    37.2%
    Operating margin
    -1583.0%
    Net margin
    0.0%
    ROE
    -2543.0%
    FCF margin
    -860.6%
    FCF yield
    -106.7%

    DARE Competitors

    CompanyTicker
    IRIDEX CorporationIRIX
    Pasithea Therapeutics CorpKTTA
    Tscan Therapeutics IncTCRX
    Estrella Immunopharma Inc.ESLA
    Marker Therapeutics IncMRKR
    SINTX Technologies IncSINT
    Biocardia IncBCDA
    Citius Pharmaceuticals IncCTXR

    Sector: Healthcare

    DARE Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    1
    Buy
    2
    Hold
    0
    Sell
    0
    Strong Sell
    0

    DARE Bull Case vs Bear Case

    Bull case

    • DARE beat EPS estimates in 87.5% of its last 8 reported quarters.
    • DARE grew quarterly revenue 499.6% year over year.

    DARE Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    29.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.14
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About DARE

    Does DARE pay dividends?

    Dare Bioscience Inc (DARE) does not currently pay a regular dividend.

    What is DARE's market cap?

    Dare Bioscience Inc (DARE) has a market capitalization of $14.37M with a current stock price of $0.74.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In